Endothelium-derived hyperpolarizing factor in the brain: Influence of sex, vessel size and disease state

Women's Health

Volumn 7, Issue 3, 2011, Pages 293-303

  Davis, Catherine M ^a   Siler, Dominic A ^a   Alkayed, Nabil J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

cerebrovascular; EDHF; EET; endothelial; endothelium derived hyperpolarizing factor; epoxyeicosatrienoic acid; ischemia; vasodilation

Indexed keywords

CYCLOOXYGENASE 1; CYTOCHROME P450; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ESTROGEN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; VANILLOID RECEPTOR 4;

BLOOD VESSEL DIAMETER; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN MICROCIRCULATION; BRAIN PERFUSION; ENDOTHELIAL DYSFUNCTION; EPHX2 GENE; GENE; GENETIC POLYMORPHISM; HUMAN; HYPERPOLARIZATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; REVIEW; SEX DIFFERENCE; SMOOTH MUSCLE RELAXATION; STROKE; VASODILATATION;

BIOLOGICAL FACTORS; BRAIN; ENDOTHELIUM, VASCULAR; EPOXIDE HYDROLASES; FEMALE; HUMANS; MALE; NITRIC OXIDE; SEX FACTORS; STROKE; VASODILATION;

EID: 79957544946     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.26     Document Type: Review

References (99)

1. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376 (1980).
2. Flammer AJ, Luscher TF: Human endothelial dysfunction: EDRFs. Pflugers Arch. 459, 1005-1013 (2010).
3. Feletou M, Vanhoutte PM: EDHF: an update. Clin. Sci. (Lond.) 117, 139-155 (2009).
4. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M: Endothelial dysfunction and vascular disease. Acta Physiol. (Oxf.) 196, 193-222 (2009).
5. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl Acad. Sci. USA 84, 9265-9269 (1987).
6. Toda N, Ayajiki K, Okamura T: Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol. Rev. 61, 62-97 (2009).
7. Hwa JJ, Ghibaudi L, Williams P, Chatterjee M: Comparison of acetylcholine-dependent relaxation in large and small arteries of rat mesenteric vascular bed. Am. J. Physiol. 266, H952-H958 (1994).
8. Tomioka H, Hattori Y, Fukao M et al.: Relaxation in different-sized rat blood vessels mediated by endothelium-derived hyperpolarizing factor: importance of processes mediating precontractions. J. Vasc. Res. 36, 311-320 (1999).
9. Shimokawa H, Yasutake H, Fujii K et al.: The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J. Cardiovasc. Pharmacol. 28, 703-711 (1996).
10. You J, Johnson TD, Marrelli SP, Bryan RM Jr: Functional heterogeneity of endothelial P2 purinoceptors in the cerebrovascular tree of the rat. Am. J. Physiol. 277, H893-H900 (1999).
11. Faraci FM: Role of endothelium-derived relaxing factor in cerebral circulation: large arteries vs. microcirculation. Am. J. Physiol. 261, H1038-H1042 (1991).
12. Cipolla MJ, Smith J, Kohlmeyer MM, Godfrey JA: SKCa and IKCa channels, myogenic tone, and vasodilator responses in middle cerebral arteries and parenchymal arterioles: effect of ischemia and reperfusion. Stroke 40, 1451-1457 (2009).
13. Cipolla MJ, Bullinger LV: Reactivity of brain parenchymal arterioles after ischemia and reperfusion. Microcirculation 15, 495-501 (2008).
14. Zhang F, Iadecola C: Nitroprusside improves blood flow and reduces brain damage after focal ischemia. Neuroreport 4, 559-562 (1993).
15. He Z, Ibayashi S, Nagao T, Fujii K, Sadoshima S, Fujishima M: L-arginine ameliorates cerebral blood flow and metabolism and decreases infarct volume in rats with cerebral ischemia. Brain Res. 699, 208-213 (1995).
16. Dawson VL, Dawson TM: Nitric oxide neurotoxicity. J. Chem. Neuroanat. 10, 179-190 (1996).
17. Prado R, Watson BD, Wester P: Effects of nitric oxide synthase inhibition on cerebral blood flow following bilateral carotid artery occlusion and recirculation in the rat. J. Cereb. Blood Flow Metab. 13, 720-723 (1993).
18. Dalkara T, Yoshida T, Irikura K, Moskowitz MA: Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology 33, 1447-1452 (1994).
19. Prado R, Watson BD, Zhao W et al.: L-arginine does not improve cortical perfusion or histopathological outcome in spontaneously hypertensive rats subjected to distal middle cerebral artery photothrombotic occlusion. J. Cereb. Blood Flow Metab. 16, 612-622 (1996).
20. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD: Gender-linked brain injury in experimental stroke. Stroke 29, 159-165; discussion 166 (1998).
21. Hurn PD, Macrae IM: Estrogen as a neuroprotectant in stroke. J. Cereb. Blood Flow Metab. 20, 631-652 (2000).
22. Watanabe Y, Littleton-Kearney MT, Traystman RJ, Hurn PD: Estrogen restores postischemic pial microvascular dilation. Am. J. Physiol. Heart Circ. Physiol. 281, H155-H160 (2001).
23. Mcneill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN: Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 33, 1685-1691 (2002).
24. Pickard J, Tamura A, Stewart M, Mcgeorge A, Fitch W: Prostacyclin, indomethacin and the cerebral circulation. Brain Res. 197, 425-431 (1980).
25. Charpie JR, Schreur KD, Papadopoulos SM, Webb RC: Endothelium dependency of contractile activity differs in infant and adult vertebral arteries. J. Clin. Invest. 93, 1339-1343 (1994).
26. Willis AP, Leffler CW: Endothelial NO and prostanoid involvement in newborn and juvenile pig pial arteriolar vasomotor responses. Am. J. Physiol. Heart Circ. Physiol. 281, H2366-H2377 (2001).
27. 2 synthase expression after cerebral ischemia-reperfusion. J. Cereb. Blood Flow Metab. 26, 491-501 (2006).
28. Dogan A, Temiz C, Turker RK, Egemen N, Baskaya MK: Effect of the prostacyclin analogue, iloprost, on infarct size after permanent focal cerebral ischemia. Gen. Pharmacol. 27, 1163-1166 (1996).
29. Shima K, Umezawa H, Chigasaki H, Okuyama S, Araki H: Stable prostacyclin improves postischaemic microcirculatory changes in hypertensive rats. Acta Neurochir. (Wien.) 137, 89-95 (1995).
30. 2) protects rat cortical neurons in culture against hypoxia/reoxygenation and glutamate-induced injury. Neurosci. Lett. 160, 106-108 (1993).
31. De La Torre JC: Synergic activity of combined prostacyclin: dimethyl sulfoxide in experimental brain ischemia. Can. J. Physiol. Pharmacol. 69, 191-198 (1991).
32. 2 synthesis by human endothelial cells. Prostaglandins Leukot. Med. 22, 159-171 (1986).
33. Scotland RS, Madhani M, Chauhan S et al.: Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 111, 796-803 (2005).
34. Bolton TB, Lang RJ, Takewaki T: Mechanisms of action of noradrenaline and carbachol on smooth muscle of guinea-pig anterior mesenteric artery. J. Physiol. 351, 549-572 (1984).
35. + conductance. Circ. Res. 65, 199-204 (1989).
36. Chen G, Suzuki H, Weston AH: Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br. J. Pharmacol. 95, 1165-1174 (1988).
37. Feletou M, Vanhoutte PM: Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br. J. Pharmacol. 93, 515-524 (1988).
38. Komori K, Lorenz RR, Vanhoutte PM: Nitric oxide, ACh, and electrical and mechanical properties of canine arterial smooth muscle. Am. J. Physiol. 255, H207-H212 (1988).
39. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 396, 269-272 (1998).
40. Feletou M, Vanhoutte PM: Endotheliumderived hyperpolarizing factor. Clin. Exp. Pharmacol. Physiol. 23, 1082-1090 (1996).
41. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH: EDHF: bringing the concepts together. Trends Pharmacol. Sci. 23, 374-380 (2002).
42. Marrelli SP, Eckmann MS, Hunte MS: Role of endothelial intermediate conductance KCa channels in cerebral EDHF-mediated dilations. Am. J. Physiol. Heart Circ. Physiol. 285, H1590-H1599 (2003).
43. Mcneish AJ, Sandow SL, Neylon CB, Chen MX, Dora KA, Garland CJ: Evidence for involvement of both IKCa and SKCa channels in hyperpolarizing responses of the rat middle cerebral artery. Stroke 37, 1277-1282 (2006).
44. +]: a functional approach to separating EDHF- and EDNO-related mechanisms in perfused rat mesenteric arterial bed. J. Cardiovasc. Pharmacol. 21, 423-429 (1993).
45. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A: Importance of endothelium-derived hyperpolarizing factor in human arteries. J. Clin. Invest. 100, 2793-2799 (1997).
46. Nagao T, Illiano S, Vanhoutte PM: Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-L-arginine in rats. Am. J. Physiol. 263, H1090-H1094 (1992).
47. Faraci FM, Lynch C, Lamping KG: Responses of cerebral arterioles to ADP: eNOS-dependent and eNOS-independent mechanisms. Am. J. Physiol. Heart Circ. Physiol. 287, H2871-H2876 (2004).
48. Marrelli SP, Khorovets A, Johnson TD, Childres WF, Bryan RM Jr: P2 purinoceptor-mediated dilations in the rat middle cerebral artery after ischemia-reperfusion. Am. J. Physiol. 276, H33-H41 (1999).
49. 2+ regulation after ischemia/reperfusion produces potentiated endothelium-derived hyperpolarizing factor-mediated dilations. Stroke 33, 2285-2291 (2002).
50. Golding EM, You J, Robertson CS, Bryan RM Jr: Potentiated endothelium-derived hyperpolarizing factor-mediated dilations in cerebral arteries following mild head injury. J. Neurotrauma 18, 691-697 (2001).
51. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R: Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94, 3341-3347 (1996).
52. Schildmeyer LA, Bryan RM Jr: Effect of NO on EDHF response in rat middle cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 282, H734-H738 (2002).
53. Waldron GJ, Ding H, Lovren F, Kubes P, Triggle CR: Acetylcholine-induced relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide synthase. Br. J. Pharmacol. 128, 653-658 (1999).
54. Huang A, Sun D, Smith CJ et al.: In eNOS knockout mice skeletal muscle arteriolar dilation to acetylcholine is mediated by EDHF. Am. J. Physiol. Heart Circ. Physiol. 278, H762-H768 (2000).
55. Luksha L, Agewall S, Kublickiene K: Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 202, 330-344 (2009).
56. Zygmunt PM, Plane F, Paulsson M, Garland CJ, Hogestatt ED: Interactions between endothelium-derived relaxing factors in the rat hepatic artery: focus on regulation of EDHF. Br. J. Pharmacol. 124, 992-1000 (1998).
57. McCulloch AI, Randall MD: Sex differences in the relative contributions of nitric oxide and EDHF to agonist-stimulated endothelium-dependent relaxations in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 123, 1700-1706 (1998).
58. White RM, Rivera CO, Davison CA: Nitric oxide-dependent and -independent mechanisms account for gender differences in vasodilation to acetylcholine. J. Pharmacol. Exp. Ther. 292, 375-380 (2000).
59. Liu MY, Hattori Y, Fukao M, Sato A, Sakuma I, Kanno M: Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle. Br. J. Pharmacol. 132, 1035-1046 (2001).
60. Luksha L, Poston L, Gustafsson JA, Hultenby K, Kublickiene K: The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J. Physiol. 577, 945-955 (2006).
61. Sokoya EM, Burns AR, Marrelli SP, Chen J: Myoendothelial gap junction frequency does not account for sex differences in EDHF responses in rat MCA. Microvasc. Res. 74, 39-44 (2007).
62. Golding EM, Kepler TE: Role of estrogen in modulating EDHF-mediated dilations in the female rat middle cerebral artery. Am. J. Physiol. Heart Circ. Physiol. 280, H2417-H2423 (2001).
63. Edwards G, Thollon C, Gardener MJ et al.: Role of gap junctions and EETs in endothelium-dependent hyperpolarization of porcine coronary artery. Br. J. Pharmacol. 129, 1145-1154 (2000).
64. Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78, 415-423 (1996).
65. Fisslthaler B, Popp R, Kiss L et al.: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401, 493-497 (1999).
66. Matoba T, Shimokawa H, Nakashima M et al.: Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J. Clin. Invest. 106, 1521-1530 (2000).
67. Feletou M, Vanhoutte PM: Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler. Thromb. Vasc. Biol. 26, 1215-1225 (2006).
68. Campbell WB, Fleming I: Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers. Arch. 459, 881-895 (2010).
69. Alkayed NJ, Narayanan J, Gebremedhin D, Medhora M, Roman Rj, Harder DR: Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke 27, 971-979 (1996).
70. Medhora M, Narayanan J, Harder D: Dual regulation of the cerebral microvasculature by epoxyeicosatrienoic acids. Trends Cardiovasc. Med. 11, 38-42 (2001).
71. Amruthesh SC, Falck JR, Ellis EF: Brain synthesis and cerebrovascular action of epoxygenase metabolites of arachidonic acid. J. Neurochem. 58, 503-510 (1992).
72. 2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am. J. Physiol. 264, H327-H335 (1993).
73. Rosolowsky M, Campbell WB: Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim. Biophys. Acta 1299, 267-277 (1996).
74. Vanrollins M, Kaduce TL, Fang X, Knapp HR, Spector AA: Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J. Biol. Chem. 271, 14001-14009 (1996).
75. Weintraub NL, Fang X, Kaduce TL, Vanrollins M, Chatterjee P, Spector AA: Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ. Res. 81, 258-267 (1997).
76. Alkayed NJ, Birks EK, Hudetz AG, Roman RJ, Henderson L, Harder DR: Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline cerebral blood flow. Am. J. Physiol. 271, H1541-H1546 (1996).
77. Zhang W, Otsuka T, Sugo N et al.: Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39, 2073-2078 (2008).
78. Rubanyi GM, Vanhoutte PM: Nature of endothelium-derived relaxing factor: are there two relaxing mediators? Circ. Res. 61, II61-1167 (1987).
79. Gebremedhin D, Harder DR, Pratt PF, Campbell WB: Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: role of a cytochrome P450 metabolite. J. Vasc. Res. 35, 274-284 (1998).
80. Woodman OL, Boujaoude M: Chronic treatment of male rats with daidzein and 17 β-oestradiol induces the contribution of EDHF to endothelium-dependent relaxation. Br. J. Pharmacol. 141, 322-328 (2004).
81. Imig JD, Falck JR, Wei S, Capdevila JH: Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J. Vasc. Res. 38, 247-255 (2001).
82. Dong H, Jiang Y, Cole WC, Triggle CR: Comparison of the pharmacological properties of EDHF-mediated vasorelaxation in guinea-pig cerebral and mesenteric resistance vessels. Br. J. Pharmacol. 130, 1983-1991 (2000).
83. Gebremedhin D, Ma YH, Falck JR, Roman RJ, Vanrollins M, Harder DR: Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am. J. Physiol. 263, H519-H525 (1992).
84. + channels. J. Cardiovasc. Pharmacol. (2010).
85. 2 and TRPV4 channels regulate endothelial calcium in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 292, H1390-H1397 (2007).
86. You J, Golding EM, Bryan RM Jr: Arachidonic acid metabolites, hydrogen peroxide, and EDHF in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 289, H1077-H1083 (2005).
87. + in endothelium-derived hyperpolarizing factor-linked dilatation in rat middle cerebral artery. Stroke 36, 1526-1532 (2005).
88. Sokoya EM, Burns AR, Setiawan CT, Coleman HA, Parkington HC, Tare M: Evidence for the involvement of myoendothelial gap junctions in EDHF-mediated relaxation in the rat middle cerebral artery. Am. J. Physiol. Heart Circ. Physiol. 291, H385-H393 (2006).
89. Dietrich HH, Horiuchi T, Xiang C, Hongo K, Falck JR, Dacey RG Jr: Mechanism of ATP-induced local and conducted vasomotor responses in isolated rat cerebral penetrating arterioles. J. Vasc. Res. 46, 253-264 (2009).
90. Wu Y, Huang A, Sun D, Falck JR, Koller A, Kaley G: Gender-specific compensation for the lack of NO in the mediation of flow-induced arteriolar dilation. Am. J. Physiol. Heart Circ. Physiol. 280, H2456-H2461 (2001).
91. Huang A, Sun D, Jacobson A, Carroll MA, Falck JR, Kaley G: Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ. Res. 96, 376-383 (2005).
92. Koerner IP, Zhang W, Cheng J, Parker S, Hurn PD, Alkayed NJ: Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front. Biosci. 13, 2833-2841 (2008).
93. Hercule HC, Schunck WH, Gross V et al.: Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler. Thromb. Vasc. Biol. 29, 54-60 (2009).
94. Morton JS, Rueda-Clausen CF, Davidge ST: Mechanisms of endothelium-dependent vasodilation in male and female, young and aged offspring born growth restricted. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R930-R938 (2010).
95. Larsen BT, Gutterman DD, Sato A et al.: Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ. Res. 102, 59-67 (2008).
96. Zhang W, Koerner IP, Noppens R et al.: Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27, 1931-1940 (2007).
97. Zhang L, Ding H, Yan J et al.: Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population. Pharmacogenet. Genomics 18, 45-51 (2008).
98. Koerner IP, Jacks R, Debarber AE et al.: Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J. Neurosci. 27, 4642-4649 (2007).
99. Zhang W, Iliff JJ, Campbell CJ, Wang RK, Hurn PD, Alkayed NJ: Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia. J. Cereb. Blood Flow Metab. 29, 1475-1481 (2009).